Abstract
The scarcity of human cadaver islets for transplantation in patients with Diabetes Mellitus (DM) has necessitated the search for alternative islet sources. With advancing islet biology research, Islet-Like Clusters (ILCs) derived from stem cells have demonstrated potential for treating DM and in novel drug discovery programs for drug and cytotoxicity testing. In vitro differentiation of ILCs from stem cells also provides an opportunity to mimic the in vivo islet developmental pathways. In vitro derived ILCs are often considered immature as they do not respond to glucose challenges efficiently. However, the in vitro and in vivo performance of ILCs can be improved by pharmacological preconditioning. In this review, we discuss how ILCs generated from human postnatal tissues can be utilized as an in-vitro model to study cytotoxicity, drug screening and enhancement of transplantation efficacy. The use of human cadaver islets is not permitted for research purposes in India. Under these restrictions, the application of ILCs in drug screening and their role in complementing, reducing, and replacing animal testing will evolve as a reliable platform for in vitro screening as well as for stem cell-based treatment in DM.
Keywords: Diabetes mellitus, drug screening, glucose responsiveness, islet like cluster, insulin secretion, islet transplantation.
Current Diabetes Reviews
Title:Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research
Volume: 17 Issue: 5
Author(s): Avinash Kharat, Bhawna Chandravanshi, Avinash Sanap, Supriya Kheur and Ramesh Bhonde*
Affiliation:
- Regenerative Medicine Laboratory, Dr. D. Y. Patil Dental College & Hospital, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune,India
Keywords: Diabetes mellitus, drug screening, glucose responsiveness, islet like cluster, insulin secretion, islet transplantation.
Abstract: The scarcity of human cadaver islets for transplantation in patients with Diabetes Mellitus (DM) has necessitated the search for alternative islet sources. With advancing islet biology research, Islet-Like Clusters (ILCs) derived from stem cells have demonstrated potential for treating DM and in novel drug discovery programs for drug and cytotoxicity testing. In vitro differentiation of ILCs from stem cells also provides an opportunity to mimic the in vivo islet developmental pathways. In vitro derived ILCs are often considered immature as they do not respond to glucose challenges efficiently. However, the in vitro and in vivo performance of ILCs can be improved by pharmacological preconditioning. In this review, we discuss how ILCs generated from human postnatal tissues can be utilized as an in-vitro model to study cytotoxicity, drug screening and enhancement of transplantation efficacy. The use of human cadaver islets is not permitted for research purposes in India. Under these restrictions, the application of ILCs in drug screening and their role in complementing, reducing, and replacing animal testing will evolve as a reliable platform for in vitro screening as well as for stem cell-based treatment in DM.
Export Options
About this article
Cite this article as:
Kharat Avinash , Chandravanshi Bhawna , Sanap Avinash , Kheur Supriya and Bhonde Ramesh *, Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research, Current Diabetes Reviews 2021; 17 (5) : e101220189128 . https://dx.doi.org/10.2174/1573399817999201214224559
DOI https://dx.doi.org/10.2174/1573399817999201214224559 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design A Review of Oxidative Stress Related Genes and New Antioxidant Therapy in Diabetic Nephropathy
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors
Current Pharmaceutical Design Nitric Oxide Synthase Inhibition and Renal Injury
Current Enzyme Inhibition The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology Role of Salt and Potassium in Hypertension and the Associated Organ Damages
Current Hypertension Reviews Glomerular Endothelium and its Impact on Glomerular Filtration Barrier in Diabetes: Are the Gaps Still Illusive?
Current Medicinal Chemistry Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia
CNS & Neurological Disorders - Drug Targets Chelation Therapy for Metal Intoxication: Comments from a Thermodynamic Viewpoint
Mini-Reviews in Medicinal Chemistry Risk Factors Identification and Prediction of Anemia among Women in Bangladesh using Machine Learning Techniques
Current Women`s Health Reviews Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Current Diabetes Reviews Podocyte Mitosis – A Catastrophe
Current Molecular Medicine The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes
Current Diabetes Reviews Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets